Cooperative group portfolio in locally advanced non-small-cell lung cancer

Are we making progress?

Corey J. Langer, Heather Wakelee, Joan Schiller, Hak Choy, Frances Shepherd, Everett E. Vokes, Alex Adjei, Paul Baas, Nagahiro Saijo, David R. Gandara

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Combined-modality therapy has emerged as the standard of care for fit patients with unresectable, locally advanced non-small-cell lung cancer (NSCLC). Concurrent chemotherapy/radiation has demonstrated therapeutic superiority compared with sequential or asynchronous chemotherapy and radiation in this setting. The role of consolidation or maintenance therapy with targeted agents or conventional cytotoxic agents remains unclear. We explore the portfolio of clinical trials being conducted in locally advanced NSCLC by North American cooperative oncology groups as well as ongoing trials in Europe and Japan. These efforts focus on radiation dose escalation using image-guided radiation therapy as well as newer cytotoxic agents (eg, pemetrexed) and targeted therapies (eg, cetuximab, bevacizumab, and etc) thus far unexplored in this setting.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalClinical Lung Cancer
Volume9
Issue number2
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cytotoxins
Radiation
Pemetrexed
Image-Guided Radiotherapy
Drug Therapy
Combined Modality Therapy
Standard of Care
Japan
Therapeutics
Clinical Trials
Cetuximab
Bevacizumab

Keywords

  • Cetuximab
  • Chemoradiation therapy
  • Etoposide
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Langer, C. J., Wakelee, H., Schiller, J., Choy, H., Shepherd, F., Vokes, E. E., ... Gandara, D. R. (2008). Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress? Clinical Lung Cancer, 9(2), 85-91. https://doi.org/10.3816/CLC.2008.n.013

Cooperative group portfolio in locally advanced non-small-cell lung cancer : Are we making progress? / Langer, Corey J.; Wakelee, Heather; Schiller, Joan; Choy, Hak; Shepherd, Frances; Vokes, Everett E.; Adjei, Alex; Baas, Paul; Saijo, Nagahiro; Gandara, David R.

In: Clinical Lung Cancer, Vol. 9, No. 2, 01.01.2008, p. 85-91.

Research output: Contribution to journalReview article

Langer, CJ, Wakelee, H, Schiller, J, Choy, H, Shepherd, F, Vokes, EE, Adjei, A, Baas, P, Saijo, N & Gandara, DR 2008, 'Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?', Clinical Lung Cancer, vol. 9, no. 2, pp. 85-91. https://doi.org/10.3816/CLC.2008.n.013
Langer, Corey J. ; Wakelee, Heather ; Schiller, Joan ; Choy, Hak ; Shepherd, Frances ; Vokes, Everett E. ; Adjei, Alex ; Baas, Paul ; Saijo, Nagahiro ; Gandara, David R. / Cooperative group portfolio in locally advanced non-small-cell lung cancer : Are we making progress?. In: Clinical Lung Cancer. 2008 ; Vol. 9, No. 2. pp. 85-91.
@article{e2725224fa924769b610c9a889fde08e,
title = "Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?",
abstract = "Combined-modality therapy has emerged as the standard of care for fit patients with unresectable, locally advanced non-small-cell lung cancer (NSCLC). Concurrent chemotherapy/radiation has demonstrated therapeutic superiority compared with sequential or asynchronous chemotherapy and radiation in this setting. The role of consolidation or maintenance therapy with targeted agents or conventional cytotoxic agents remains unclear. We explore the portfolio of clinical trials being conducted in locally advanced NSCLC by North American cooperative oncology groups as well as ongoing trials in Europe and Japan. These efforts focus on radiation dose escalation using image-guided radiation therapy as well as newer cytotoxic agents (eg, pemetrexed) and targeted therapies (eg, cetuximab, bevacizumab, and etc) thus far unexplored in this setting.",
keywords = "Cetuximab, Chemoradiation therapy, Etoposide, Radiation therapy",
author = "Langer, {Corey J.} and Heather Wakelee and Joan Schiller and Hak Choy and Frances Shepherd and Vokes, {Everett E.} and Alex Adjei and Paul Baas and Nagahiro Saijo and Gandara, {David R.}",
year = "2008",
month = "1",
day = "1",
doi = "10.3816/CLC.2008.n.013",
language = "English (US)",
volume = "9",
pages = "85--91",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Cooperative group portfolio in locally advanced non-small-cell lung cancer

T2 - Are we making progress?

AU - Langer, Corey J.

AU - Wakelee, Heather

AU - Schiller, Joan

AU - Choy, Hak

AU - Shepherd, Frances

AU - Vokes, Everett E.

AU - Adjei, Alex

AU - Baas, Paul

AU - Saijo, Nagahiro

AU - Gandara, David R.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Combined-modality therapy has emerged as the standard of care for fit patients with unresectable, locally advanced non-small-cell lung cancer (NSCLC). Concurrent chemotherapy/radiation has demonstrated therapeutic superiority compared with sequential or asynchronous chemotherapy and radiation in this setting. The role of consolidation or maintenance therapy with targeted agents or conventional cytotoxic agents remains unclear. We explore the portfolio of clinical trials being conducted in locally advanced NSCLC by North American cooperative oncology groups as well as ongoing trials in Europe and Japan. These efforts focus on radiation dose escalation using image-guided radiation therapy as well as newer cytotoxic agents (eg, pemetrexed) and targeted therapies (eg, cetuximab, bevacizumab, and etc) thus far unexplored in this setting.

AB - Combined-modality therapy has emerged as the standard of care for fit patients with unresectable, locally advanced non-small-cell lung cancer (NSCLC). Concurrent chemotherapy/radiation has demonstrated therapeutic superiority compared with sequential or asynchronous chemotherapy and radiation in this setting. The role of consolidation or maintenance therapy with targeted agents or conventional cytotoxic agents remains unclear. We explore the portfolio of clinical trials being conducted in locally advanced NSCLC by North American cooperative oncology groups as well as ongoing trials in Europe and Japan. These efforts focus on radiation dose escalation using image-guided radiation therapy as well as newer cytotoxic agents (eg, pemetrexed) and targeted therapies (eg, cetuximab, bevacizumab, and etc) thus far unexplored in this setting.

KW - Cetuximab

KW - Chemoradiation therapy

KW - Etoposide

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=43349085498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43349085498&partnerID=8YFLogxK

U2 - 10.3816/CLC.2008.n.013

DO - 10.3816/CLC.2008.n.013

M3 - Review article

VL - 9

SP - 85

EP - 91

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -